Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-modified Dextromethorphan

Avanir Pharmaceuticals, Inc. AVNR and Concert Pharmaceuticals, Inc. announced today that they have entered into an exclusive license agreement that provides Avanir worldwide rights to develop and commercialize Concert's deuterium-modified dextromethorphan (d-DM) for the potential treatment of neurological and psychiatric disorders.  The agreement includes the rights to multiple deuterium-modified dextromethorphan compounds.